CA2251022A1 - Medicaments actifs enrobes a administration orale - Google Patents

Medicaments actifs enrobes a administration orale Download PDF

Info

Publication number
CA2251022A1
CA2251022A1 CA 2251022 CA2251022A CA2251022A1 CA 2251022 A1 CA2251022 A1 CA 2251022A1 CA 2251022 CA2251022 CA 2251022 CA 2251022 A CA2251022 A CA 2251022A CA 2251022 A1 CA2251022 A1 CA 2251022A1
Authority
CA
Canada
Prior art keywords
unit
stomach
active drug
intestine
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2251022
Other languages
English (en)
Inventor
Colin R. Gardner
Mandana Asgharnejad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608929.7A external-priority patent/GB9608929D0/en
Priority claimed from GBGB9619063.2A external-priority patent/GB9619063D0/en
Application filed by Individual filed Critical Individual
Publication of CA2251022A1 publication Critical patent/CA2251022A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dose unitaire de médicaments à administration par voie orale constituée d'un médicament actif présentant un diamètre efficace et d'une composition superficielle permettant le transport de cette dose de l'estomac au duodenum une fois que le chyme se trouve pratiquement entièrement déversé de l'estomac dans l'intestin et avant que le médicament actif ne soit libéré de la dose. Le médicament actif présente un rythme d'absorption qui est considérablement affecté par la présence concomitante d'aliments dans l'estomac. Le diamètre efficace de la dose empêche sa libération dans l'estomac avant le transfert du chyme gastrique, tandis que la composition superficielle est constituée d'un revêtement entérique empêchant la libération du médicament actif dans l'estomac mais permettant cette libération dans l'intestin.
CA 2251022 1996-04-10 1997-04-07 Medicaments actifs enrobes a administration orale Abandoned CA2251022A1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US1517696P 1996-04-10 1996-04-10
US60/015,176 1996-04-10
GB9608929.7 1996-04-29
GBGB9608929.7A GB9608929D0 (en) 1996-04-29 1996-04-29 Oral coated firbrinogen receptor antagonist composition
US2399996P 1996-08-12 1996-08-12
US60/023,999 1996-08-12
GB9619063.2 1996-09-12
GBGB9619063.2A GB9619063D0 (en) 1996-09-12 1996-09-12 Oral coated active drugs

Publications (1)

Publication Number Publication Date
CA2251022A1 true CA2251022A1 (fr) 1997-10-16

Family

ID=27451442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2251022 Abandoned CA2251022A1 (fr) 1996-04-10 1997-04-07 Medicaments actifs enrobes a administration orale

Country Status (5)

Country Link
EP (1) EP0914099A1 (fr)
JP (1) JPH11510514A (fr)
AU (1) AU2447097A (fr)
CA (1) CA2251022A1 (fr)
WO (1) WO1997037641A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910773D0 (en) * 1999-05-11 1999-07-07 West Pharm Serv Drug Res Ltd Novel single unit coated dosage forms that can be used to minimise the effect of food on the absorption of drugs from the gastrointestinal tract
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
US11458104B1 (en) * 2018-06-21 2022-10-04 Mission Pharmacal Company Enteric coated tiopronin tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
US5446056A (en) * 1993-11-24 1995-08-29 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists

Also Published As

Publication number Publication date
EP0914099A1 (fr) 1999-05-12
JPH11510514A (ja) 1999-09-14
WO1997037641A1 (fr) 1997-10-16
AU2447097A (en) 1997-10-29

Similar Documents

Publication Publication Date Title
US7029701B2 (en) Composition for the treatment and prevention of ischemic events
KR100949273B1 (ko) 복합제제
ES2220602T3 (es) Sistema de administracion pulsatil controlada en el tiempo de farmacos.
KR100389602B1 (ko) 소화관하부용출형피부캅셀제제
ES2699444T3 (es) Formas de dosificación oral que incluyen un agente antiplaquetario y un inhibidor ácido
EP1453487B2 (fr) Forme de dose pharmaceutique a films multiples
KR100955669B1 (ko) ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
US20110045028A1 (en) Sustained release preparation
ES2303314T3 (es) Formulaciones de liberacion prolongada de dipiridamol y procedimiento para su preparacion.
CA2606740A1 (fr) Preparations de quinine
KR20040063975A (ko) 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
JP6657420B2 (ja) クロピドグレル及びアスピリンを含む複合製剤
CN101426371A (zh) 艾普拉唑的药物组合物
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CA2684219C (fr) Formes dosifiees orales de cephalotaxine
US20030129236A1 (en) Multiple pulse extended release formulations of clindamycin
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US5980951A (en) Oral coated active drugs
US6136794A (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
CA2251022A1 (fr) Medicaments actifs enrobes a administration orale
WO1997035615A1 (fr) Compositions et techniques d'inhibition de la formation de caillots
US20190374474A1 (en) Pharmaceutical compositions and methods for weight loss
US6129932A (en) Compositions for inhibiting platelet aggregation
JP5044572B2 (ja) イミダゾリルアルキル−ピリジンの安定な投薬製剤
WO2016166732A1 (fr) Salicylate de colchicine et ses utilisations

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead